TNFRSF17 and cancer: One of the major concerns in developing BCMA-targeting biologics is that BCMA on the cell surface is cleaved by γ-secretase, resulting in the downregulation of cell-surface BCMA [10] and limiting the efficacy of BCMA-targeted biological drugs on cancer cells.